subcutaneous injection. It is a novel drug that targets a specific signaling pathway involved in the progression of pulmonary arterial hypertension (PAH).

Indication: Winrevair is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to:

• Increase exercise capacity
• Improve WHO functional class (FC)
• Reduce the risk of clinical worsening events

Mechanism of Action: Winrevair is an activin signaling inhibitor. It works by binding to activin A and other members of the transforming growth factor-β (TGF-β) superfamily. By doing this, it modulates the signaling balance in the pulmonary arteries. This action helps to reverse the structural tissue changes that occur in PAH, such as vascular proliferation, and reduces inflammation, leading to a decrease in pulmonary artery pressure.